| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRIPT |
| Uniprot No | Q9P021 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-101aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMVCEKCE KKLGTVITPD TWKDGARNTT ESGGRKLNEN KALTSKKARF DPYGKNKFST CRICKSSVHQ PGSHYCQGCA YKKGICAMCG KKVLDTKNYK QTSV |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRIPT重组蛋白研究的参考文献示例(注：以下内容为模拟示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**: "Expression and Functional Characterization of Recombinant CRIPT in E. coli"
**作者**: Smith, J., et al.
**摘要**: 本研究成功在大肠杆菌系统中表达了带有His标签的重组CRIPT蛋白，通过亲和层析纯化获得高纯度蛋白。功能实验表明，重组CRIPT能够与突触后PDZ结构域蛋白特异性结合，验证了其在突触组装中的潜在作用。
2. **文献名称**: "Structural Insights into CRIPT Protein via Recombinant Expression in Mammalian Cells"
**作者**: Lee, Y., et al.
**摘要**: 利用哺乳动物HEK293细胞表达系统制备了全长CRIPT重组蛋白，并通过冷冻电镜解析其三维结构。研究发现，CRIPT的C端结构域对突触前膜的结合至关重要，为神经发育疾病机制提供了新视角。
3. **文献名称**: "Recombinant CRIPTO Enhances Neurite Outgrowth in Cortical Neurons"
**作者**: Martinez, R., et al.
**摘要**: 通过杆状病毒-昆虫细胞系统表达重组CRIPT蛋白，发现其能显著促进体外培养的皮层神经元突触生长，提示其在神经再生治疗中的应用潜力。
4. **文献名称**: "CRISPR/Cas9-mediated Knockout Combined with Recombinant CRIPT Rescue in Synaptic Dysfunction Models"
**作者**: Wang, T., et al.
**摘要**: 结合基因编辑技术，利用重组CRIPT蛋白成功恢复了CRIPT敲除小鼠神经元中的突触传递功能，证实了其在维持突触可塑性中的必要性。
---
**建议**：实际研究中，可通过PubMed、Web of Science等平台以关键词“CRIPT recombinant protein”、“cysteine-rich intracellular protein expression”检索最新文献，或关注其与CRIPTO/TDGF1等相似蛋白的交叉研究。
CRISPR-interacting protein (CRIPT), a recombinant protein of growing interest, is closely associated with CRISPR-Cas systems, which revolutionized genome editing. Originally identified as a conserved component in certain CRISPR-Cas pathways, CRIPT plays a regulatory or auxiliary role in DNA targeting or repair processes. Its recombinant form is engineered for biotechnological and therapeutic applications, leveraging its ability to interact with CRISPR-associated machinery.
Recombinant CRIPT is produced via heterologous expression systems (e.g., E. coli, yeast, or mammalian cells) to ensure proper folding and post-translational modifications. Researchers optimize codons and purification tags (e.g., His-tag) to enhance yield and solubility. Its structural domains, often including nucleic acid-binding motifs or Cas-protein interaction sites, are studied to refine CRISPR toolkits—improving editing precision, reducing off-target effects, or enabling novel functions like base or prime editing.
CRIPT’s applications span gene therapy, agricultural biotechnology, and molecular diagnostics. In therapeutics, it aids in developing safer CRISPR-based treatments for genetic disorders. In research, it serves as a modular component to engineer synthetic Cas variants or modulate DNA repair pathways (e.g., favoring HDR over NHEJ). Challenges include minimizing immunogenicity in clinical use and scaling production cost-effectively. Ongoing studies focus on structure-function relationships and fusion partners (e.g., deaminases, reverse transcriptases) to expand CRISPR versatility. As CRISPR technologies evolve, recombinant CRIPT remains pivotal in bridging mechanistic insights with real-world applications.
×
